CPAP vs BiPAP: clinical decision tree

Most patients walking out of a sleep lab in India walk out with a prescription for some form of positive airway pressure (PAP) therapy. The difference between CPAP and BiPAP is not a preference — it is a clinical distinction that hinges on what your sleep study actually showed, what you tolerate, and what underlying physiology is driving the apneas. This guide walks through the decision the way a respiratory physician would.

What OSA is, and what CPAP treats

Obstructive sleep apnea (OSA) is the repeated partial or complete collapse of the upper airway during sleep. The soft tissues of the pharynx fall inward, airflow stops or drops, blood oxygen falls, the brainstem registers the disturbance, a brief awakening follows, the airway reopens, and the cycle repeats — often 15, 30, or 60+ times an hour in moderate to severe cases.

Continuous positive airway pressure (CPAP) treats this mechanically. A blower produces a continuous stream of room air at a fixed pressure, delivered through a mask, that pneumatically splints the airway open. The pressure is the same during inspiration and expiration. It is a remarkably simple therapy and, where it works, remarkably effective: a correctly titrated CPAP eliminates almost all obstructive events in most OSA patients and restores normal sleep architecture within a few nights to a few weeks.

Modern CPAPs are most often auto-CPAPs (APAPs): rather than a fixed pressure, the device continuously varies pressure within a prescribed min/max window to match the patient’s breath-by-breath airway resistance. This is easier to tolerate than fixed pressure and is the dominant mode for first-line therapy in uncomplicated OSA.

When BiPAP is preferred

BiPAP (bilevel positive airway pressure) provides two separate pressures — a higher one on inspiration (IPAP) and a lower one on expiration (EPAP). The difference between them, the pressure support, is what the patient feels as assistance on each breath. BiPAP is indicated when CPAP alone is not enough — either because the patient cannot tolerate the expiratory pressure of a high CPAP setting, or because the underlying physiology needs more than pneumatic splinting.

Primary indications for BiPAP over CPAP:

• Severe OSA requiring high pressure. When the titrated pressure needed to maintain the airway approaches 15–18 cmH₂O, the expiratory burden of holding a single continuous pressure that high can make sleep uncomfortable or cause air swallowing. BiPAP drops the pressure during expiration, preserves airway stent on inspiration, and is better tolerated.
• CPAP intolerance. A subset of patients simply cannot sleep against a high CPAP. Switching to BiPAP with a lower EPAP often salvages therapy that would otherwise be abandoned.
• Central sleep apnea (CSA). In CSA the airway is not obstructed; the brainstem simply fails to send the drive-to-breathe signal periodically. CPAP alone is ineffective and sometimes worsens CSA (treatment-emergent or complex sleep apnea). BiPAP with a backup rate (ST mode — spontaneous-timed) delivers breaths when the patient does not trigger them.
• Complex sleep apnea (CompSAS). A mixed picture where obstructive events coexist with central events. Adaptive servo-ventilation (ASV) is the most sophisticated option; BiPAP-ST is a step down from ASV and often adequate.
• COPD-OSA overlap syndrome. Patients with both COPD and OSA benefit from the expiratory pressure relief of BiPAP. The EPAP prevents airway collapse, and the higher IPAP offsets some of the work-of-breathing cost imposed by airway obstruction and hyperinflation.
• Obesity hypoventilation syndrome (OHS). Sustained daytime hypercapnia in the obese patient usually needs more than simple CPAP. BiPAP, often with a target volume assured pressure support (AVAPS / TVAPS) overlay, is the clinical standard. (Masa JF et al, Pickwick trial (Lancet 2019))
• Neuromuscular disease (ALS, muscular dystrophy, post-polio) where respiratory muscle weakness impairs both the ability to move tidal volume and the ability to eliminate CO₂. BiPAP with backup rate is the entry-level home ventilation setup; patients may progress to volume-controlled ventilators as disease progresses.

How your sleep study informs the choice

An Indian polysomnography (PSG) report has a few fields that matter for the CPAP-vs-BiPAP decision:

• AHI (Apnea-Hypopnea Index): the total events per hour. <5 normal, 5–15 mild, 15–30 moderate, ≥30 severe. CPAP is first-line across all severity levels in pure OSA.
• Central AI vs obstructive AI breakdown: if the centrals are >50% of total events or >5/hour absolute, CPAP alone is unlikely to work — BiPAP-ST or ASV is the direction.
• Titrated pressure: the pressure at which the study showed elimination of events. If the titration went to 14–15 cmH₂O and events persisted, BiPAP is likely to come up in the consult.
• CO₂ monitoring (where done): a baseline transcutaneous or arterial CO₂ elevation pushes the decision toward bilevel therapy with a backup rate.
• Sleep architecture: REM-predominant apnea, REM desaturation, and REM-related AHI >30 all keep the therapy within CPAP/BiPAP (rather than escalating to ventilation) but influence the titration target.

The right conversation to have with your sleep physician: “which of my events are obstructive, which are central, and at what pressure did the lab titrate me out?” The answer usually picks the device class.

A simplified decision flow

The clinical reasoning, compressed:

1. Pure OSA, AHI 5–30, titration under 14 cmH₂O: CPAP or APAP is first-line.
2. Pure OSA, AHI > 30 and titration ≥ 14–15 cmH₂O: BiPAP often preferred for comfort and adherence.
3. Central events dominant, or CompSAS pattern: BiPAP-ST or ASV. Not CPAP.
4. OHS or significant daytime hypercapnia: BiPAP, commonly with volume-assurance target (AVAPS/TVAPS).
5. COPD + OSA overlap: BiPAP.
6. Neuromuscular disease with nocturnal hypoventilation: BiPAP-ST with a backup rate.

This is the reasoning, not a prescription. Device selection is a physician call that depends on your full clinical picture.

Indian-market price difference

2026 pricing ranges across the primary brands in India:

• CPAP / APAP: ₹25,000 – ₹80,000.
  • Entry-level fixed-pressure CPAP from smaller brands from around ₹25,000.
  • Established APAPs (ResMed AirSense, Philips DreamStation, BMC G3 Auto) from ₹45,000–₹80,000.
• BiPAP-S (bilevel-spontaneous): ₹50,000 – ₹1,20,000.
• BiPAP-ST (spontaneous-timed, with backup rate): ₹80,000 – ₹1,60,000.
• BiPAP with volume assurance (AVAPS / TVAPS): ₹1,40,000 – ₹2,50,000.
• ASV: ₹1,60,000 – ₹3,00,000+.

Prices vary by configuration (humidifier, mask kit, cellular modem) and by distribution channel. Independent prescriber-channel pricing is typically 10–15% below retail; hospital-channel pricing is commonly 10% above.

What to buy isn’t always what to prescribe for

A common Indian buying pattern: patient diagnosed with moderate-to-severe OSA, prescribed BiPAP because the titration was high, but buys CPAP on cost grounds. This is usually a mistake. If the titration was performed properly and found CPAP insufficient, a cheaper CPAP is not cheaper in practice — it is just non-therapeutic. Buying the class your sleep physician prescribed is the first-order decision; negotiating within that class on price, ecosystem, and warranty is the second-order decision.

If cost is a real constraint, talk to your physician about whether an auto-BiPAP with a reduced pressure-support window might be adequate, whether a reconditioned unit from a reputable distributor is available, or whether a rental is a workable bridge while the diagnosis settles.

The takeaway

CPAP and BiPAP are not competing options for the same problem. They treat overlapping but distinct clinical pictures. A correct CPAP prescription solves OSA; a correct BiPAP prescription solves the broader family of sleep-disordered breathing that includes central events, hypoventilation, and high-pressure intolerance. Pick the device class your sleep study and your physician support, then pick the specific unit on ecosystem, accuracy, and service — not the other way around.

This guide is editorial opinion and general information. It is not medical advice. Consult your physician for therapy decisions, and verify all specifications with the manufacturer before purchase.